Tesamorelin + Ipamorelin · 13 MG

This research blend combines two growth hormone–axis peptides in a single lyophilized vial: tesamorelin and ipamorelin. The formulation pairs a stabilized GHRH receptor agonist with a selective growth hormone secretagogue receptor (GHS-R) agonist, allowing concurrent investigation of GHRH and ghrelin / GHS pathway activation. Tesamorelin is a synthetic 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminus and an extended plasma half-life, FDA-approved as Egrifta® for visceral adipose tissue reduction in HIV-associated lipodystrophy. Ipamorelin is a selective pentapeptide GHS-R1a agonist studied for its specificity over cortisol, prolactin, ACTH, and aldosterone pathways. The 13 mg blend (10 mg Tesamorelin + 3 mg Ipamorelin) is intended as a comparative pharmacology research blend for investigators studying paired GHRH and GHS-R pathway signaling in preclinical models of body composition, growth hormone dynamics, and metabolic endpoints.

Benefits (Research Focus)

• Combined GHRH + GHS-R activation — studied for paired pathway stimulation of the somatotropic axis

• Pulsatile GH release — investigated for physiologic-pattern growth hormone release in research models

• IGF-1 axis signaling — explored for downstream hepatic IGF-1 production and somatotropic endpoints

• Visceral adipose research — examined for VAT-specific endpoints via the tesamorelin component in lipodystrophy models

• Hormone selectivity — researched for ipamorelin's reported minimal off-target effects on cortisol, prolactin, and ACTH

What Researchers Look At

• Plasma GH and IGF-1 dynamics following paired peptide administration

• Pulsatile vs sustained GH release across paired GHRH and GHS-R stimulation

• Visceral adipose tissue (VAT) measurements via CT or MRI in lipodystrophy research models

• Cortisol, prolactin, and ACTH response panels (selectivity markers)

• Comparative pharmacology versus single-component administration of either peptide

Quick Specs

• Form: Lyophilized white powder

• Tesamorelin: 10 mg per vial

• Ipamorelin: 3 mg per vial

• Total Peptide Content: 13 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC (per component)

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound 1: Tesamorelin

• Synonyms: TH9507; Egrifta (FDA-approved brand name)

• Class: Stabilized GHRH(1-44) analog with N-terminal trans-3-hexenoic acid modification; 44 amino acids

• Formula / M.W.: C₂₂₁H₃₆₆N₇₂O₆₇S, ~5135.86 g/mol

• CAS: 218949-48-5

• Compound 2: Ipamorelin

• Synonyms: NNC 26-0161

• Class: Selective ghrelin / GHS-R1a agonist; pentapeptide

• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

• Formula / M.W.: C₃₈H₄₉N₉O₅, ~711.85 g/mol

• CAS: 170851-70-4

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Tesamorelin / Ipamorelin Blend VPeptide Canada — November 21, 2025

• Tesamorelin / Ipamorelin VPeptide — April 23, 2026

• Tesamorelin / Ipamorelin VPeptide — July 1, 2026